Brought to you by 
CNS companies Axonyx and TorreyPines reverse merge
29 Jun 2006
Executive Summary
Combining complementary CNS programs, Axonyx (acquires and develops compounds for Alzheimer's disease) has agreed to reverse merge with TorreyPines Therapeutics (small-molecule treatments for neurological diseases), keeping the TorreyPines name and president and CEO Neil Kurtz.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Includes Contract
- Intra-Biotech Deal
- Payment Includes Stock
- Reverse Acquisition
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
CNS companies Axonyx and TorreyPines reverse merge
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice